Treatment Options

Hypochondroplasia is a lifelong genetic condition classified under skeletal dysplasia, and currently, there is no cure for it. However, some individuals and families may consider various treatment options aimed at improving growth, mobility, independence, or overall quality of life, including the use of growth hormone or limb lengthening procedures. Treatment decisions are highly personal; while some individuals pursue these treatment options, others may choose not to. There is no single right choice, and different people may make different decisions based on their unique circumstances, goals, values, and experiences. This page provides balanced information about treatment options that may be discussed in relation to hypochondroplasia. Families should always seek advice from appropriately qualified healthcare professionals when considering treatment decisions.

People consider treatment for different reasons related to conditions like hypochondroplasia and other forms of skeletal dysplasia. Potential goals for seeking treatment options may include increasing adult height through methods such as growth hormone therapy or limb lengthening, improving reach and access, enhancing independence, boosting mobility or physical function, reducing the impact of environmental barriers, and ultimately improving quality of life. 

Some families primarily focus on treatment to increase height, while others may prioritize improving reach, independence, mobility, participation, or overall quality of life. Different individuals place varying importance on these goals, and their priorities often evolve over time.

At the same time, many individuals with hypochondroplasia choose not to pursue treatment and live full, active, and successful lives without it.

Within the skeletal dysplasia community, perspectives on treatment options vary widely. Some people see treatments as valuable opportunities to enhance function and independence, while others advocate for a societal focus on accessibility, acceptance, and inclusion rather than altering the individual.

Most families find that making treatment decisions involves balancing potential benefits, risks and side effects, practical demands, emotional impact, family circumstances, personal values, and the wishes of the individual involved. 

Because experiences and priorities differ significantly, treatment decisions are often best made over time, with access to accurate information and appropriate medical guidance.

Limb lengthening is currently the treatment option with the greatest potential impact on adult height and reach in individuals with hypochondroplasia, a form of skeletal dysplasia. 

Limb lengthening is an orthopaedic surgical procedure that gradually increases the length of bones in the arms, legs, or both, offering hope for those affected by conditions like hypochondroplasia. 

Modern techniques for limb lengthening have evolved considerably over recent decades and may involve external fixation, internal lengthening devices, or a combination of approaches to achieve optimal results. 

Potential goals of limb lengthening may include: 

- increasing height 

- improving reach 

- enhancing independence in daily activities 

- improving access to environments designed for average-height individuals 

- reducing reliance on adaptations or environmental modifications. 

Depending on the approach used, limb lengthening may involve lengthening of the legs, arms, or both, addressing the needs of individuals with skeletal dysplasia. 

It is important to note that limb lengthening is a major undertaking, usually involving surgery, rehabilitation, physical therapy, regular follow-up, and a significant time commitment. 

A long-term study of extensive limb lengthening in achondroplasia and hypochondroplasia included 75 patients, consisting of 9 with hypochondroplasia. In that study, the average lengthening for individuals with hypochondroplasia was 17 cm, with a range of 10 to 25 cm. The authors reported that most patients returned to activities of normal living, but complications occurred, including one serious neurological complication. 

While the study demonstrated that substantial height gains are possible through limb lengthening, it also highlighted the significant commitment, prolonged rehabilitation, and risk of complications associated with treatment options. 

Limb lengthening remains one of the most personal and sometimes controversial topics within the skeletal dysplasia community. Little People of America states that its position is neither to advocate for nor condemn extended limb lengthening but to provide information to support thoughtful decision-making. The statement emphasizes that families should carefully consider medical, psychological, educational, financial, social, and long-term implications. 

Families considering limb lengthening may wish to speak with: 

- orthopaedic surgeons experienced in skeletal dysplasia 

- physiotherapists and occupational therapists 

- geneticists or skeletal dysplasia specialists 

- psychologists or counselors 

- adults or families with different lived experiences of choosing or not choosing surgery. 

Important questions may include: 

- What are the realistic goals of treatment? 

- What procedures would be involved? 

- What are the possible risks and complications? 

- How long would treatment and rehabilitation take? 

- How might treatment affect school, work, family life, or emotional wellbeing? 

- What happens if complications occur? 

- What support will be available during recovery? 

- How will the person with hypochondroplasia be involved in the decision-making process?

Growth hormone has been studied for decades in children with hypochondroplasia, a type of skeletal dysplasia, and remains one of the most extensively researched treatment options for this condition. 

The primary aim of treatment with growth hormone is to increase growth velocity and potentially enhance adult height. 

However, the evidence regarding the effectiveness of growth hormone in hypochondroplasia is mixed and somewhat disappointing. Some studies indicate that children may experience faster growth during treatment, particularly in the early stages. Nevertheless, the impact of growth hormone on final adult height remains uncertain, with more recent data suggesting that it may not significantly improve adult height for many children with hypochondroplasia. 

A long-term study involving six children with hypochondroplasia who were treated with recombinant growth hormone reported an improvement in growth velocity, but no significant enhancement in final height. The researchers concluded that while growth hormone seemed to have some effect on growth, it was insufficient to achieve an adequate final height. 

A more recent abstract from the ESPE 2024 conference noted that recombinant growth hormone was not effective in improving adult height in a small group of children with hypochondroplasia. The authors acknowledged that the data remains limited and that alternative therapies, including limb lengthening, should be considered for addressing short stature in children with hypochondroplasia. 

Taken together, current evidence suggests that while growth hormone may increase growth velocity in some children, particularly early in treatment, its effect on final adult height appears to be limited. 

Families may wish to discuss the following questions with their healthcare team: 

- Is growth hormone an appropriate treatment option for my child? 

- Does my child have growth hormone deficiency, or is treatment being considered solely for short stature? 

- What realistic benefits might we expect? 

- What are the limitations of this treatment? 

- What monitoring will be required? 

- What is known about long-term outcomes? 

- What are the potential side effects and risks? 

- Is this treatment available or covered in our healthcare system? 

It's important to note that growth hormone is not routinely used in all countries and may not be available or funded in every healthcare system.

The most significant advances in hypochondroplasia treatment options are currently occurring in the area of targeted therapies that aim to address the underlying biology of FGFR3-related skeletal dysplasia. These therapies include those that target the FGFR3 pathway directly, as well as those that work through related biological pathways involved in bone growth and potentially enhance the effectiveness of growth hormone therapies. Several of these limb lengthening and other treatment options are currently being investigated in clinical trials, with additional programs continually entering development. Researchers are studying the safety and effectiveness of these therapies, their impact on growth, body proportions, function, quality of life, and long-term outcomes, as well as identifying which individuals with skeletal dysplasia may benefit most. To learn more about current research, clinical trials, and emerging therapies, please visit our Research section.

For many individuals and families, quality of life is influenced by much more than height alone. Research in both hypochondroplasia and achondroplasia increasingly recognizes that outcomes such as independence, participation, pain, function, mental wellbeing, and overall quality of life are important alongside height. Factors that may contribute to wellbeing include: physical health, independence, accessibility, participation in school, work, and community life, relationships, confidence and self-esteem, and support from family and peers. Treatment options, such as growth hormone therapy and limb lengthening, may be considered, but whether or not these treatments are pursued, many people with hypochondroplasia lead fulfilling lives and achieve their personal goals despite the challenges associated with skeletal dysplasia.

Treatment decisions regarding conditions like hypochondroplasia and other skeletal dysplasias can be complex and deeply personal. What feels right for one individual or family may not feel right for another, especially when considering treatment options such as growth hormone therapy or limb lengthening. Our role is not to recommend a particular path but to support informed decision-making by providing balanced information, connecting families with resources, and encouraging conversations with experienced healthcare professionals.